Chemotherapy Protocols

Chemotherapy Regimens for HER2-negative breast cancer (including HER2-low cancers)

1. TC  (Docetaxel plus cyclophosphamide
2. AC-T, dose dense (paclitaxel followed by doxorubicin plus cyclophosphamide)
3. TAC (Docetaxel, doxorubicin and cyclophosphamide)
4. FEC (fluorouracil, epirubicin, plus cyclophosphamide)
5. FAC (fluorouracil, doxorubicin plus cyclophosphamide)
6. FEC followed by weekly paclitaxel
7. FEC followed by weekly docetaxel
8. Trastuzumab deruxtecan

Chemotherapy Regimens for HER2-positive breast cancer

1. TH (paclitaxel and trastuzumab)
2. TCH (docetaxel, carboplatin, and trastuzumab)
3. TCHP (trastuzumab, pertuzumab, carboplatin, and docetaxel)
4. AC-TH (doxorubicin plus cyclophosphamide followed by paclitaxel plus trastuzumab)
5. AC-THP (doxorubicin and cyclophosphamide followed by paclitaxel, trastuzumab, and pertuzumab)
6. FEC-THP (FEC followed by docetaxel, pertuzumab, and trastuzumab)
7. THP-FEC-H (neoadjuvant docetaxel, trastuzumab, and pertuzumab followed by adjuvant FEC, followed by trastuzumab
8. THP (docetaxel, trastuzumab, and pertuzumab)
9. Ado-trastuzumab emtansine

Chemotherapy Regimens for small and large bowel cancer:

1. Capecitabine plus bevacizumab
2. Modified FOLFOX6 (fluorouracil plus leucovorin and oxaliplatin)
3. Modified FOLFOX6 plus bevacizumab
4. Modified FOLFOX7
5. Modified FOLFOX7 plus bevacizumab
6. Capecitabine plus oxaliplatin for small intestinal adenocarcinoma
7. Capecitabine plus oxaliplatin (XELOX, CAPOX) for colorectal cancer
8. XELOX/CAPOX plus bevacizumab for colorectal cancer
9. FOLFIRI (fluorouracil plus leucovorin and irinotecan)
10. FOLFIRI plus bevacizumab
11. FOLFOXIRI (FOLFOX plus irinotecan)
12. FOLFOXIRI plus bevacizumab for metastatic colorectal cancer
13. Modified FOLFOXIRI plus panitumumab for colorectal cancer
14. Neoadjuvant FOLFIRINOX (FOLFIRI plus oxaliplatin) for rectal cancer
15. Single-agent cetuximab
16. Single-agent panitumumab
17. Cetuximab plus irinotecan
18. FOLFIRI plus cetuximab
19. FOLFIRI plus panitumumab

Immunotherapy for small and large bowel cancer:

1. Nivolumab monotherapy for microsatellite-unstable (mismatch repair-deficient) advanced cancer
2. Pembrolizumab monotherapy for microsatellite-unstable (mismatch repair-deficient) advanced cancer
3. Nivolumab plus ipilimumab for microsatellite-unstable (mismatch repair-deficient) metastatic colorectal cancer

Chemotherapy Regimens for pancreatic cancer:

1. Adjuvant gemcitabine
2. Adjuvant gemcitabine plus capecitabine
3. Modified FOLFIRINOX
4. Gemcitabine monotherapy
5. Gemcitabine plus nanoparticle albumin-bound paclitaxel (nabpaclitaxel)
6. Gemcitabine plus capecitabine
7. Gemcitabine plus cisplatin
8. FOLFIRINOX (fluorouracil plus leucovorin, irinotecan, and oxaliplatin)
9. Modified FOLFIRINOX
10. Modified FOLFOX6 (fluorouracil plus leucovorin and oxaliplatin)
11. iposomal irinotecan and 5-FU for metastatic pancreatic cancer
12. Pembrolizumab monotherapy for microsatellite-unstable (mismatch repair-deficient) advanced cancer

Chemotherapy Regimens for hepatobiliary cancer:

1. Modified FOLFOX6
2. Capecitabine and oxaliplatin
3. Single agent gemcitabine for adjuvant treatment of biliary tract cancer
4. emcitabine and capecitabine (GEMCAP)
5. Single agent gemcitabine for metastatic biliary tract cancer
6. Gemcitabine and cisplatin for locally advanced or metastatic biliary tract cancer
7. Gemcitabine and oxaliplatin (GEMOX) for locally advanced or metastatic biliary tract cancer
8. Modified gemcitabine and oxaliplatin (GEMOX) for advanced gallbladder cancer
9. Gemcitabine and capecitabine (GEMCAP) for advanced biliary tract cancer
10. FOLFIRI (fluorouracil plus leucovorin and irinotecan) plus bevacizumab
11. Gemcitabine and pegylated liposomal doxorubicin for advanced HCC
12. Gemcitabine and oxaliplatin (GEMOX) for advanced HCC
13. Pembrolizumab monotherapy
14. Nivolumab monotherapy
15. Nivolumab plus ipilimumab for advanced HCC

Chemotherapy Regimens for non-small cell lung cancer:

1. Carboplatin plus docetaxel
2. Carboplatin plus nanoparticle albumin-bound paclitaxel (nabpaclitaxel)
3. Carboplatin, paclitaxel, atezolizumab, and bevacizumab
4. Carboplatin plus pemetrexed
5. Cisplatin plus pemetrexed
6. Gemcitabine plus carboplatin
7. Gemcitabine plus cisplatin (GC)
8. Paclitaxel carboplatin
9. Paclitaxel, carboplatin, and bevacizumab
10. Pembrolizumab monotherapy
11. Pembrolizumab, nabpaclitaxel, and carboplatin
12. Pembrolizumab, paclitaxel, and carboplatin
13. Pembrolizumab, pemetrexed, and carboplatin
14. Nivolumab monotherapy
15. Vinorelbine plus cisplatin

Regimens for small cell lung cancer:

1. Carboplatin plus etoposide
2. Cisplatin (60 mg/m2) plus etoposide
3. Cisplatin (80 mg/m2) plus etoposide
4. Irinotecan plus cisplatin
5. Atezolizumab plus carboplatin and etoposide
6. Single-agent topotecan